RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections

Ads

You May Also Like

Advaxis Appoints Al Blunt, M.D., as its Vice President of Medical

PRINCETON, N.J., March 07, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology ...

TiGenix obtains commercial production license for expanded manufacturing facility

PRESS RELEASE TiGenix obtains commercial production license for expanded manufacturing facility - Provides capacity ...

Rhythm Pharmaceuticals Reports Second Quarter 2018 Financial Results

-- Completed Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in ...